Completion of Lead Clinical Candidate PH-762 Dose Escalation Trial for Treatment of Skin Cancer with Favorable Safety and Pathology DataKey Development Agreements Secured for Nonclinical Toxicology and...
Live Presentation and Q&A: Wednesday, April 29, 2026 12 PM EDTKing of Prussia, Pennsylvania--(Newsfile Corp. - April 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
Phio invites investors, advisors and analysts with an interest in the life sciences sector to attend this virtual eventR. Todd Plott, M.D., Chief Medical Officer, Epiphany Dermatology will join Robert...
Investors and Advisors, and Life Sciences Analysts are Invited to Attend the New York City Event; Virtual Webcast Link Available BelowKing of Prussia, Pennsylvania--(Newsfile Corp. - April 9, 2026) - Phio...
A Critical Next Step in Advancing Phio's PH-762 Program to Treat Cutaneous CarcinomasKing of Prussia, Pennsylvania--(Newsfile Corp. - March 30, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage...
Prestigious Late-Breaking Research Session Positions PH-762 as a Promising New PD-1 Directed Immunotherapy Candidate on March 28, 2026 at 3 PM (MDT)King of Prussia, Pennsylvania--(Newsfile Corp. - March...
Registration link below for Wednesday March 18, 2026 at 4 PM EDT Phio invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend...
The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.comKing...
Treatment Phase for Lead Clinical Candidate PH-762 Dose Escalation Trial is Complete with Favorable Safety, Tolerability and Pathology Data 2025 Financings and Warrant Exercises Strengthen Balance Sheet...
Live Presentation and Q&A: Monday, March 9, 2026 10 AM EDTCEO to Discuss INTASYL Platform and PH-762 Phase 1b Results King of Prussia, Pennsylvania--(Newsfile Corp. - March 5, 2026) - Phio Pharmaceuticals...